SYT12: A promising drug target and biomarker for the treatment of neurodegenerative diseases

Target Name: SYT12

NCBI ID: G91683

SYT12

SYT12: A promising drug target and biomarker for the treatment of neurodegenerative diseases

Synaptotagmin 12 (SYT12) is a protein that plays a crucial role in the structure and function of the nervous system. It is a member of the neurotrophic factor receptor tyrosine kinase (NGT) family, which is involved in the regulation of neural growth, survival, and differentiation. SYT12 is expressed in various tissues of the central nervous system (CNS) and is involved in the development, maintenance, and modulation of neural circuits.

SYT12 has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells, which results in the degenerative symptoms associated with the diseases.

The neurotrophic factor receptor tyrosine kinase (NGT) family plays a crucial role in the regulation of neural growth, survival, and differentiation. The NG

Protein Name: Synaptotagmin 12

Functions: Synaptic vesicle phosphoprotein that enhances spontaneous neurotransmitter release but does not effect induced neurotransmitter release (By similarity). Unlike other synaptotagmins, it does not bind Ca(2+) or phospholipids (By similarity). Essential for mossy-fiber long-term potentiation in the hippocampus (By similarity)

The "SYT12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYT12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets